Vascular Signature Mapping of Brain Tumor Genotypes (VASIM)

March 5, 2025 updated by: Matthias van Osch, Leiden University Medical Center
A glioma is a primary brain tumor in adults that is characterized by a highly variable, but overall poor survival. The optimal timing of treatment is in part determined by the expected biological behavior of the tumor. At present the expected biological behavior, determined by the tumor genotype, can only be determined by tissue analysis, which requires brain surgery. Non-invasive and improved diagnostic methods are sought to obtain insight into the molecular profile of the tumor and the expected biological behavior to avoid surgery performed solely for diagnostic purposes. Vascularization is an important aspect of the biological behavior of a primary brain tumor. Tumor vascularization characteristics can be assessed by Magnetic Resonance Imaging (MRI), but with the currently available technology this can only be achieved with unacceptably long scan times. In this proposal, the investigators will develop and optimize a novel MRI protocol to gather a large set of quantitative vascularization parameters within an acceptable scan time. The hypothesis is that from such a 'vascular signature' the tumor genotype can be inferred by means of machine learning.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Objective of the study:

The primary objective is to develop and clinically validate a fast multi-parametric MRI acquisition technique, for non-invasive and comprehensive characterization of the tumor's vascularization, 'vascular signature mapping', at 3 Tesla (3T) and 7 Tesla (7T) MRI.

The secondary objective is to limit difficult and time-consuming visual interpretation of the acquired vascular information by developing a computer-aided diagnostic algorithm that automatically and accurately predicts the brain tumor genotype from the vascular signature maps.

Study design:

The study 'Vascular Signature Mapping for Brain Tumor Genotypes' is a multi-center observational diagnostic study, which consists of two parts. The first part of this study aims to develop and optimize a new MRI protocol that will exploit the effect of contrast agent on the MRI signal to infer information on the vascular properties of a tumor. It combines scans during the pre-contrast injection phase, the dynamic phase during and right after contrast agent injection, as well as the quasi static post-contrast phase. This research will focus on studying the optimal way of encoding the vascular architecture into the MRI signal and the decoding approach, In addition, the image processing methodology will be optimized. The second part of this study is a proof-of-concept clinical study. This part aims to link the vascular parameters with molecular profiles of tumors by using the collected data for the development of machine learning algorithms for predicting the tumor's genotype based on its vascular signature.

Study population:

The study population consists of 3 cohorts, all aged over 18 years, able to provide written informed consent and without contraindications for contrast-enhanced MRI. The first cohort, for development and optimization of the protocol, consists of 60 patients scheduled for brain MRI as part of their standard clinical diagnostic procedure and in whom contrast agent (CA) administration is part of their standard radiological assessment. These patients do not necessarily have a brain tumor as the purpose here is to develop and evaluate the vascular signature mapping sequence in general. The second cohort consists of 20 glioma patients in whom the vascular signature mapping sequence is tested and for a direct comparison between 3T and 7T MRI, where the 3T scan is an extension of the diagnostic care and the additional 7T scan is optional. The third cohort, for the clinical proof-of-concept study, consists of 100 adult patients referred for biopsy or surgery of suspected glioma.

Primary study parameters/outcome of the study:

The endpoint of the first part of the study is a novel MRI protocol for characterization of the vessel architecture, assessed with respect to the signal-to-noise ratio (SNR) and the ability to obtain vascular Information. The main parameters that will be used for characterization of the vasculature are physiological parameters including the vessel architecture, cerebral blood volume (CBV), cerebral blood flow (CBF), mean transit time (MTT), and oxygenation level.

The main study end point of the second part of the study is the accuracy of automatic classification of the tumor's genotype. The accuracy of the new method will be compared to the current state-of-the-art reference method based on conventional MRI.

Secondary study parameters/outcome of the study:

Baseline characteristics of subjects (including age, sex, Karnofsky performance status, tumor histology, molecular parameters (1p/19q, Isocitrate Dehydrogenase (IDH1/2) and 06-Methylguanine-DNA Methyltransferase (MGMT) status), tumor location, supportive and antitumor treatment). In addition, the outcome (e.g. mortality, tumor progression, radiation necrosis, functioning of patients) will be used as study parameter. The outcome will be determined from the follow-up scans after 3 and 6 months, where the criterion for progression or pseudo-progression is determined by the outcome of the scan.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

For the first cohort, the additional burden will not be substantial for the participant. The additional scan time will not exceed 10 minutes and therefore the impact on the patient will be limited. For the second and third cohort, the additional burden includes a prolonged MRI examination at a clinical MRI scanner (3T) and an optional additional examination at 7T MRI including additional CA injection. The ultrahigh field 7T MRI system is commonly used for research and no serious adverse events have been reported. Patients participating in this study will have no personal benefit; their participation aids in the development of a novel MRI method for the non-invasive determination of the tumor's molecular profile. Moreover, there is a small chance that the additional 7T MRI scan would provide more Information on the status of the disease in the participant.

Study Type

Observational

Enrollment (Estimated)

180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Netherlands
      • Leiden, Netherlands, 2333ZA
        • Not yet recruiting
        • Leiden University Medical Center
        • Contact:
        • Contact:
        • Contact:
          • Matthias van Osch, Professor
      • Rotterdam, Netherlands, 3000CA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The first cohort, for protocol development and optimization, consists of 60 patients scheduled for brain MRI as part of their standard clinical diagnostic procedure and in whom contrast administration is part of their standard radiological assessment. These patients do not necessarily have a brain tumor as the purpose is to develop and evaluate the vascular signature mapping sequence in general. The second cohort consists of 20 glioma patients in whom the vascular signature mapping sequence is tested and for a direct comparison between 3T and 7T MRI, where the 3T scan is an extension of the diagnostic care and the additional 7T scan is optional. The third cohort, for the clinical proof-of-concept study, consists of 100 adult patients referred for biopsy or surgery of suspected glioma.

Description

Inclusion Criteria:

  • Patients scheduled for brain MRI with contrast injection as part of the clinical diagnostic procedure (cohort 1)
  • Patients diagnosed with suspected glioma scheduled for brain MRI as part of the clinical diagnostic procedure (cohort 2)
  • Patients with (suspected) glioma referred for tumor biopsy or resection (cohort 3)
  • Age ≥ 18 years (all cohorts)
  • Signed informed consent (all cohorts)

Exclusion Criteria:

  • Subjects with contra-indications for an MRI exam
  • Subjects with reduced kidney function because of the risk on developing nephrogenic systemic fibrosis (NSF) under gadolinium-based contrast injection
  • Subjects with pregnancy
  • Subjects undergoing a clinical protocol that requires scanning during CA injection (cohort 1)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients scheduled for brain MRI with contrast injection
Inclusion at Erasmus MC and LUMC: The first cohort consists of 60 patients scheduled for brain MRI as part of their standard clinical diagnostic procedure and in whom contrast agent administration is part of their standard radiological assessment. These patients do not necessarily have a brain tumor as the purpose here is to develop and evaluate the vascular signature mapping sequence in general. Usually, such testing would be done in healthy volunteers, but contrast agent is required for the vascular signature mapping sequence. To avoid unnecessary contrast agent administration, the sequence will be tested in this patient cohort instead. In this study part, the outcome is the optimized protocol itself, with which the investigators could obtain additional information about the vascular structure throughout the brain. Therefore this group of subjects is expected to be sufficiently homogeneous for the research aim of this part of the study.
Device: X-ray (optional)
Optional X-ray scan to assess the safety for undergoing an MR examination.
Other: Question list
Questionnaire for contra-indications for an MR examination.
Patients diagnosed with suspected glioma scheduled for brain MRI
Inclusion at Erasmus MC and LUMC: The second cohort consists of 20 glioma patients in whom the vascular signature mapping sequence is tested specifically for glioma and for a direct comparison between 3T and 7T, where the 3T scan is an extension of the diagnostic care and the additional 7T scan is optional. This number of patients is sufficient to provide information on differences in the ability to measure tumor vascularity between 3T and 7T, while minimizing the extra patient burden.
Device: X-ray (optional)
Optional X-ray scan to assess the safety for undergoing an MR examination.
Other: Question list
Questionnaire for contra-indications for an MR examination.
Device: Philips Achieva 7T MRI
Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
Other Names:
  • Philips Ingenia (Elition) 3T MRI
  • GE Healthcare (MR750/Signa Premier) 3T MRI
Combination product: Additional contrast injection
Contrast agent administration for the additional 7T scan (optional).
Patients with (suspected) glioma

Inclusion at Erasmus MC and LUMC: The third cohort consists of 100 adult patients referred for biopsy or surgery of suspected glioma. The diagnosis of glioma is based on a multitude of factors, such as initial presentation (headaches, vomiting, potential changes in character). Based on the initial presentation a patient may be suspected of having a glioma, which is often confirmed using imaging. Although a true conclusion requires analysis of tissue, in an overwhelming majority of the cases (99%), analysis of the imaging is sufficient to confirm the presence of glioma. Thus, the investigators can be relatively certain about the inclusion of glioma patients based on the initial presentation and imaging alone.

Since there is a close collaboration with the Neurology departments of both the LUMC and Haaglanden Medical Center (HMC) in The Hague, the investigators broaden their inclusion capacity also to this hospital.
Device: X-ray (optional)
Optional X-ray scan to assess the safety for undergoing an MR examination.
Other: Question list
Questionnaire for contra-indications for an MR examination.
Device: Philips Achieva 7T MRI
Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
Other Names:
  • Philips Ingenia (Elition) 3T MRI
  • GE Healthcare (MR750/Signa Premier) 3T MRI
Combination product: Additional contrast injection
Contrast agent administration for the additional 7T scan (optional).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Optimized MR protocol
Time Frame: 6 months
MR protocol optimized for SNR and the ability to obtain vascular information
6 months
Vessel architecture
Time Frame: 4 years
Structure of vessels and tortuosity
4 years
Cerebral blood volume
Time Frame: 4 years
To characterize the tumor's vasculature
4 years
Cerebral blood flow
Time Frame: 4 years
To characterize the tumor's vasculature
4 years
Transit time parameters
Time Frame: 4 years
Timing parameters used to characterize the tumor vasculature
4 years
Vascular oxygenation level
Time Frame: 4 years
Oxygen-related parameters that describe the tumor's vasculature
4 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Basic subject characteristics
Time Frame: 4 years
Age, gender, KPS performance score
4 years
Tumor histology
Time Frame: 4 years
Structural information about the tumor, cell type and architectural pattern
4 years
Tumor molecular parameters
Time Frame: 4 years
IDH mutation, MGMT status
4 years
Treatment information
Time Frame: 4 years
Radiotherapy dose, chemotherapy scheme
4 years
Tumor progression scored on follow-up MR scan
Time Frame: 4 years
Assessment of tumor progression versus pseudo-progression based on scoring of follow-up MR scans by an experienced physician.
4 years
Radiation necrosis evaluated on follow-up MR scan
Time Frame: 4 years
Assessment based on evaluation of follow-up MR scans by an experienced physician.
4 years
Mortality
Time Frame: 4 years
Survival time and occurrence of death
4 years
KPS score at follow-up of 3 and 6 months
Time Frame: 4 years
Performance score providing information about the functioning of patients
4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Leiden University Medical Center

Collaborators

Erasmus Medical Center

Investigators

  • Principal Investigator: Matthias JP van Osch, Prof Dr Ir, Leiden University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 16, 2022

Primary Completion (Estimated)

March 31, 2026

Study Completion (Estimated)

March 31, 2026

Study Registration Dates

First Submitted

February 8, 2022

First Submitted That Met QC Criteria

March 1, 2022

First Posted (Actual)

March 11, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 5, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • VSMBTG

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glioma

Clinical Trials on X-ray (optional)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe